Chapter 15
Transporter–Xenobiotic Interactions: An Important Aspect of Drug Development Studies
Gang Luo, Richard Ridgewell,
Thomas Guenthner,
Richard Ridgewell
Covance Laboratories Inc., Madison, Wisconsin, USA
Search for more papers by this authorThomas Guenthner
University of Illinois at Chicago, Chicago, Illinois, USA
Search for more papers by this authorGang Luo, Richard Ridgewell,
Thomas Guenthner,
Richard Ridgewell
Covance Laboratories Inc., Madison, Wisconsin, USA
Search for more papers by this authorThomas Guenthner
University of Illinois at Chicago, Chicago, Illinois, USA
Search for more papers by this authorBook Editor(s):Chuang Lu,
Albert P. Li,
Chuang Lu
Department of DMPK, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Search for more papers by this authorAlbert P. Li
In Vitro ADMET Laboratories, Columbia, Maryland, USA
Search for more papers by this authorSummary
This chapter contains sections titled:
-
Introduction
-
Tissue Expression and Functions
-
Substrates and Inhibitors
-
Experimental Models for Studying Transporters in Drug development
-
Experimental Manipulation of Transporter Activity
-
Specific examples of Transporter Studies in Drug Discovery and development
-
Summary
-
Acronyms and Abbreviations
-
References
REFERENCES
- Aleksunes LM, Slitt AL, Maher JM, Augustine LM, Goedken MJ, Chan JY, Cherrington NJ, Klaassen CD, Manautou JE. Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol Appl Pharmacol 2008; 226(1): 74–83.
- Alissa FT, Jaffe R, Shneider BL. Update on progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2008; 46(3): 241–252.
- Allikmets R, Gerrard B, Hutchinson A, Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet 1996; 5(10): 1649–1655.
- Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 2007; 24(10): 1803–1823.
-
Ambudkar SV, Rosen BP, Gottesman MM. Workshop on ABC Transporters and Human Diseases. Drug Resist Update 2000; 3(1): 51–54.
10.1054/drup.2000.0125 Google Scholar
- Behravan J, Piquette-Miller M. Drug transport across the placenta, role of the ABC drug efflux transporters. Expert Opin Drug Metab Toxicol 2007; 3(6): 819–830.
- Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, Ling V, Chen ZS, Grinberg A, Westphal H, Klein-Szanto A, Lerro A, Kruh GD. Analysis of the in vivo functions of Mrp3. Mol Pharmacol 2005; 68(1): 160–168.
- Bennett DJ, Cooke AJ, Edwards AS. Non-steroidal LXR agonists; an emerging therapeutic strategy for the treatment of atherosclerosis. Recent Patents Cardiovasc Drug Discovery 2006; 1(1): 21–46.
- Birn H, Spiegelstein O, Christensen EI, Finnell RH. Renal tubular reabsorption of folate mediated by folate binding protein 1. J Am Soc Nephrol 2005; 16(3): 608–615.
- Bohme M, Jedlitschky G, Leier I, Buchler M, Keppler D. ATP-dependent export pumps and their inhibition by cyclosporins. Adv Enzyme Regul 1994; 34: 371–380.
- Bonge H, Hallen S, Fryklund J, Sjostrom JE. Cytostar-T scintillating microplate assay for measurement of sodium-dependent bile acid uptake in transfected HEK-293 cells. Anal Biochem 2000; 282(1): 94–101.
- Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92(16): 1295–1302.
- Brandsch M, Knutter I, Leibach FH. The intestinal H+/peptide symporter PEPT1: structure—affinity relationships. Eur J Pharm Sci 2004; 21(1): 53–60.
- Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006; 27(1): 17–24.
- Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, Pavek P. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 2007; 35(7): 1032–1041.
- Chang C, Ekins S, Bahadduri P, Swaan PW. Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev 2006; 58(12–13): 1431–1450.
- Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003; 63(14): 4048–4054.
- Choi DS, Cascini MG, Mailliard W, Young H, Paredes P, McMahon T, Diamond I, Bonci A, Messing RO. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat Neurosci 2004; 7(8): 855–861.
- Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008; 23(4): 243–253.
- Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006; 25(4): 231–259.
- Chu XY, Huskey SE, Braun MP, Sarkadi B, Evans DC, Evers R. Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J Pharmacol Exp Ther 2004; 309(1): 156–164.
- Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42(7): 1007–1017.
- Drobnik W, Lindenthal B, Lieser B, Ritter M, Christiansen Weber T, Liebisch G, Giesa U, Igel M, Borsukova H, Buchler C, Fung-Leung WP, Von Bergmann K, Schmitz G. ATP-binding cassette transporter A1 (ABCA1) affects total body sterol metabolism. Gastroenterology 2001; 120(5): 1203–1211.
- Dutt A, Heath LA, Nelson JA. P-glycoprotein and organic cation secretion by the mammalian kidney. J Pharmacol Exp Ther 1994; 269(3): 1254–1260.
- El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2-and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 2007; 320(1): 229–235.
- El-Sheikh AA, Masereeuw R, Russel FG. Mechanisms of renal anionic drug transport. Eur J Pharmacol 2008; 585(2–3): 245–255.
- Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol 2005; 9(3): 195–205.
- Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renalurate anion exchanger that regulates blood urate levels. Nature 2002; 417(6887): 447–452.
- Enomoto A, Niwa T, Kanai Y, Endou H. Urate transporter and renal hypouricemia. Rinsho Byori 2003; 51(9): 892–897.
- Eraly SA, Vallon V, Vaughn DA, Gangoiti JA, Richter K, Nagle M, Monte JC, Rieg T, Truong DM, Long JM, Barshop BA, Kaler G, Nigam SK. Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J Biol Chem 2006; 281(8): 5072–5083.
- Forbes JR, Cox DW. Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant? Am J Hum Genet 1998; 63(6): 1663–1674.
- Funk C. The role of hepatic transporters in drug elimination. Expert Opin Drug Metab Toxicol 2008; 4(4): 363–379.
- Galmarini CM. P-glycoprotein expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six chemotherapeutic drugs. J Exp Ther Oncol 2002; 2(3): 146–152.
- Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276(18): 14581–14587.
- Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr 2001; 33(6): 453–458.
- Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb—drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008; 52(7): 772–779.
- Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001; 69(3): 114–121.
- Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant proteins. Neonatology 2007; 91(4): 311–317.
- Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch 2004; 447(5): 465–468.
- Hirohashi T, Suzuki H, Sugiyama Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 1999; 274(21): 15181–15185.
- Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000; 11(3): 383–393.
- Hollenstein K, Dawson RJ, Locher KP. Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol 2007a; 17(4): 412–418.
- Hollenstein K, Frei DC, Locher KP. Structure of an ABC transporter in complex with its binding protein. Nature 2007b; 446(7132): 213–216.
- Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 1988; 85(10): 3580–3584.
- Hsing S, Gatmaitan Z, Arias IM. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 1992; 102(3): 879–885.
- Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001; 59(4): 806–813.
- Hussain K, Flanagan SE, Smith VV, Ashworth M, Day M, Pierro A, Ellard S. An ABCC8 gene mutation and mosaic uniparental isodisomy resulting in atypical diffuse congenital hyperinsulinism. Diabetes 2008; 57(1): 259–263.
- Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 2003; 64(3): 610–618.
- Inui K, Terada T, Masuda S, Saito H. Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2. Nephrol Dial Transplant 2000; 15(Suppl 6): 11–13.
- Ishizuka H, Konno K, Shiina T, Naganuma H, Nishimura K, Ito K, Suzuki H, Sugiyama Y. Species differences in the transport activity for organic anions across the bile canalicular membrane. J Pharmacol Exp Ther 1999; 290(3): 1324–1330.
- Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, Sugiyama Y. Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am J Physiol 1997; 272(1 Pt 1): G16–G22.
- Jansen PJ, Lutjohann D, Abildayeva K, Vanmierlo T, Plosch T, Plat J, von Bergmann K, Groen AK, Ramaekers FC, Kuipers F, Mulder M. Dietary plant sterols accumulate in the brain. Biochim Biophys Acta 2006; 1761(4): 445–453.
- Jedlitschky G, Hoffmann U, Kroemer HK. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2006; 2(3): 351–366.
- Jedlitschky G, Keppler D. Transport of leukotriene C4 and structurally related conjugates. Vitam Horm 2002; 64: 153–184.
- Johnson DR, Klaassen CD. Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways. Toxicol Sci 2002; 67(2): 182–189.
- Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, Schinkel AH. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 2001; 21(16): 5471–5477.
- Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002; 99(24): 15649–15654.
- Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 2003; 23(21): 7902–7908.
- Kamimoto Y, Gatmaitan Z, Hsu J, Arias IM. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem 1989; 264(20): 11693–11698.
- Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J Pharm Sci 2006; 95(12): 2673–2683.
- Kauffmann HM, Pfannschmidt S, Zoller H, Benz A, Vorderstemann B, Webster JI, Schrenk D. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology 2002; 171(2–3): 137–146.
- Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, van Tellingen O. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res 2003; 9(7): 2849–2855.
- Klaassen CD, Lu H. Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol Sci 2008; 101(2): 186–196.
- Klement JF, Matsuzaki Y, Jiang QJ, Terlizzi J, Choi HY, Fujimoto N, Li K, Pulkkinen L, Birk DE, Sundberg JP, Uitto J. Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. Mol Cell Biol 2005; 25(18): 8299–8310.
- Knopfel M, Zhao L, Garrick MD. Transport of divalent transition-metal ions is lost in small-intestinal tissue of b/b Belgrade rats. Biochemistry 2005; 44(9): 3454–3465.
- Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999; 96(12): 6914–6919.
- Koshiba S, An R, Saito H, Wakabayashi K, Tamura A, Ishikawa T. Human ABC transporters ABCG2 (BCRP) and ABCG4. Xenobiotica 2008; 38(7–8): 863–888.
- Kosters A, Karpen SJ. Bile acid transporters in health and disease. Xenobiotica 2008; 38(7–8): 1043–1071.
- Kwon Y, Kamath AV, Morris ME. Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles. J Pharm Sci 1996; 85(9): 935–939.
- Lagas JS, Vlaming ML, van Tellingen O, Wagenaar E, Jansen RS, Rosing H, Beijnen JH, Schinkel AH. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res 2006; 12(20 Pt 1): 6125–6132.
- Launay-Vacher V, Izzedine H, Karie S, Hulot JS, Baumelou A, Deray G. Renal tubular drug transporters. Nephron Physiol 2006; 103(3): 97–106.
- Lewis-Jones DI, Gazvani MR, Mountford R. Cystic fibrosis in infertility: screening before assisted reproduction: opinion. Hum Reprod 2000; 15(11): 2415–2417.
- Li F, Maag H, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci 2008; 97(3): 1109–1134.
- Li N, Zhang Y, Hua F, Lai Y. Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab Dispos 2009; 37(1): 66–73.
- Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 2007; 296(1–2): 85–95.
- Liu X, Chism JP, LeCluyse EL, Brouwer KR, Brouwer KL. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 1999a; 27(6): 637–644.
- Liu X, LeCluyse EL, Brouwer KR, Gan LS, Lemasters JJ, Stieger B, Meier PJ, Brouwer KL. Biliary excretion in primary rat hepatocytes cultured in a collagensandwich configuration. Am J Physiol 1999b; 277(1 Pt 1): G12–G21.
- Lohmann C, Gelius B, Danielsson J, Skoging-Nyberg U, Hollnack E, Dudley A, Wahlberg J, Hoogstraate J, Gustavsson L. Scintillation proximity assay for measuring uptake by the human drug transporters hOCT1, hOAT3, and hOATP1B1. Anal Biochem 2007; 366(2): 117–125.
- Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E, Gan LS. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30(7): 795–804.
- Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, Sinz M, LeCluyse E, Solon E, Brennan JM, Benedek IH, Jolley S, Gilbert D, Wang L, Lee FW, Gan LS. Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab Dispos 2003; 31(9): 1170–1175.
-
Luo G, Gan L, Guenthner T. Testing drug candidates for CYP3A4 induction. In: Zhang D, Zhu M, Humphreys W, editors. Drug Metabolism in Drug Design and Development. Hoboken, NJ: John Wiley & Sons, 2007a, pp. 545–571.
10.1002/9780470191699.ch17 Google Scholar
- Luo G, Garner CE, Xiong H, Hu H, Richards LE, Brouwer KL, Duan J, Decicco CP, Maduskuie T, Shen H, Lee FW, Gan LS. Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug–drug interaction case study. Drug Metab Dispos 2007b; 35(6): 835–840.
- MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother 2004; 53(6): 899–901.
- Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 2005; 33(7): 956–962.
- Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998; 15(8): 1160–1167.
- Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Elferink RO. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 2005; 42(5): 1091–1098.
- Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005; 7(1): E118–E133.
- Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15(1): 71–75.
- Masuda M, I'Izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H, Sugiyama Y. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res 1997; 57(16): 3506–3510.
- Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic aniontransporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 2005; 314(3): 1059–1067.
- Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, Hagey L, Schuetz JD, Boyer JL. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 2006; 43(5): 1013–1021.
- Miura M, Uno T, Tateishi T, Suzuki T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 2007; 19(3): 223–227.
- Mizuno N, Suzuki M, Kusuhara H, Suzuki H, Takeuchi K, Niwa T, Jonker JW, Sugiyama Y. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab Dispos 2004; 32(9): 898–901.
- Muller M, Roelofsen H, Jansen PL. Secretion of organic anions by hepatocytes: involvement of homologues of the multidrug resistance protein. Semin Liver Dis 1996; 16(2): 211–220.
- Nofer JR, Remaley AT. Tangier disease: still more questions than answers. Cell Mol Life Sci 2005; 62(19–20): 2150–2160.
- Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005; 33(3): 434–439.
- Ocheltree SM, Shen H, Hu Y, Keep RF, Smith DE. Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther 2005; 315(1): 240–247.
- Osato DH, Huang CC, Kawamoto M, Johns SJ, Stryke D, Wang J, Ferin TE, Herskowitz I, Giacomini KM. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 2003; 13(5): 297–301.
- Park S, Sinko PJ. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther 2005; 312(3): 1249–1256.
- Pellicoro A, Faber KN. Review article: The function and regulation of proteins involved in bile salt biosynthesis and transport. Aliment Pharmacol Ther 2007; 26(Suppl2): 149–160.
- Rajgopal A, Sierra EE, Zhao R, Goldman ID. Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities. Am J Physiol Cell Physiol 2001; 281(5): C1579–C1586.
- Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007; 26(1): 39–57.
- Roulet A, Puel O, Gesta S, Lepage JF, Drag M, Soll M, Alvinerie M, Pineau T. MDR1-deficient genotype in collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 2003; 460(2–3): 85–91.
- Ruetz S, Raymond M, Gros P. Functional expression of P-glycoprotein encoded by the mouse mdr3 gene in yeast cells. Proc Natl Acad Sci USA 1993; 90(24): 11588–11592.
- Sahi J, Milad MA, Zheng X, Rose KA, Wang H, Stilgenbauer L, Gilbert D, Jolley S, Stern RH, LeCluyse EL. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J Pharmacol Exp Ther 2003; 306(3): 1027–1034.
- Saito H, Masuda S, Inui K. Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J Biol Chem 1996; 271(34): 20719–20725.
- Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992; 267(7): 4854–4858.
- Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, Sugiyama Y. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin–Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol 2004; 66(3): 450–459.
- Sawamiphak S, Sophasan S, Endou H, Boonchird C. Functional expression of the rat organic anion transporter 1 (rOAT1) in Saccharomyces cerevisiae. Biochim Biophys Acta 2005; 1720(1–2): 44–51.
- Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77(4): 491–502.
- Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96(4): 1698–1705.
- Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94(8): 4028–4033.
- Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9(1): 105–127.
- Shen H, Smith DE, Keep RF, Xiang J, Brosius FC, 3rd. Targeted disruption of the PEPT2 gene markedly reduces dipeptide uptake in choroid plexus. J Biol Chem 2003; 278(7): 4786–4791.
- Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006; 62(3): 372–376.
- Silverman W, Locovei S, Dahl G. Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol 2008; 295(3): C761–C767.
- Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem 1992; 267(35): 24995–25002.
- Slitt AL, Cherrington NJ, Dieter MZ, Aleksunes LM, Scheffer GL, Huang W, Moore DD, Klaassen CD. trans-Stilbene oxide induces expression of genes involved in metabolism and transport in mouse liver via CAR and Nrf2 transcription factors. Mol Pharmacol 2006; 69(5): 1554–1563.
- Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999; 104(10): 1441–1447.
- Somogyi A. Renal transport of drugs: specificity and molecular mechanisms. Clin Exp Pharmacol Physiol 1996; 23(10–11): 986–989.
- Srimaroeng C, Perry JL, Pritchard JB. Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica 2008; 38(7–8): 889–935.
- Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 2003; 278(25): 22644–22649.
- Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem 2002; 277(30): 26934–26943.
- Tahara H, Kusuhara H, Fuse E, Sugiyama Y. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood–brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 2005; 33(7): 963–968.
- Takahashi N, Morita M, Maeda T, Harayama Y, Shimozawa N, Suzuki Y, Furuya H, Sato R, Kashiwayama Y, Imanaka T. Adrenoleukodystrophy: subcellular localization and degradation of adrenoleukodystrophy protein (ALDP/ABCD1) with naturally occurring missense mutations. J Neurochem 2007; 101(6): 1632–1643.
- Terada T, Inui K. Gene expression and regulation of drug transporters in the intestine and kidney. Biochem Pharmacol 2007; 73(3): 440–449.
- Terada T, Sawada K, Irie M, Saito H, Hashimoto Y, Inui K. Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2. Pflugers Arch 2000; 440(5): 679–684.
- Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, Brouwer KL. Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab Dispos 2008; 36(5): 911–915.
- Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, Raub TJ, Brouwer KL. Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos 2008; 36(1): 61–64.
- Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005; 115(5): 1333–1342.
- Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003; 304(1): 223–228.
- Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, Beare CM. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 1997; 146(1): 88–94.
- Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K. Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett 1998; 438(3): 321–324.
- Uwai Y, Saito H, Inui K. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol 2000; 409(1): 31–36.
- Van Aubel RA, Masereeuw R, Russel FG. Molecular pharmacology of renal organic anion transporters. Am J Physiol Renal Physiol 2000; 279(2): F216–F232.
- Velamakanni S, Wei SL, Janvilisri T, van Veen HW. ABCG transporters: structure, substrate specificities and physiological roles: a brief overview. J Bioenerg Biomembr 2007; 39(5–6): 465–471.
- Vig BS, Stouch TR, Timoszyk JK, Quan Y, Wall DA, Smith RL, Faria TN. Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. J Med Chem 2006; 49(12): 3636–3644.
- Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JH, Schinkel AH. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 2006; 318(1): 319–327.
- Westerfeld C, Mukai S. Stargardt's disease and the ABCR gene. Semin Ophthalmol 2008; 23(1): 59–65.
- Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000a; 68(1): 6–12.
- Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer HK, Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000b; 68(4): 345–355.
- Xia CQ, Milton MN, Gan LS. Evaluation of drug–transporter interactions using in vitro and in vivo models. Curr Drug Metab 2007a; 8(4): 341–363.
-
Xia C, Yang J, Bbalani S. Drug transporters in drug disposition, drug interactions, and drug resistance. In: Zhang D, Zhu M, Humphreys W, editors. Drug Metabolism in Drug Design and Development. Hoboken, NJ: John Wiley & Sons, 2007b, pp. 137–202.
10.1002/9780470191699.ch6 Google Scholar
- Xia CQ, Yang JJ, Gan LS. Breast cancer resistance protein in pharmacokinetics and drug–drug interactions. Expert Opin Drug Metab Toxicol 2005; 1(4): 595–611.
- Yu AM. Small interfering RNA in drug metabolism and transport. Curr Drug Metab 2007; 8(7): 700–708.
- Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 2006; 3(1): 55–61.
- Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, Borst P. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA 2005; 102(20): 7274–7279.
- Zhang EY, Knipp GT, Ekins S, Swaan PW. Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab Rev 2002; 34(4): 709–750.
- Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9(4): 310–322.
- Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008; 15(20): 1981–2039.
